Overview

GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes

Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet or Lennox-Gastaut syndromes.
Phase:
Phase 3
Details
Lead Sponsor:
GW Research Ltd
Treatments:
Cannabidiol